EOLS240517C17500
- 0.10
- 0.000.00%
Evolus Newsroom
Director David Gill Sells 10,361 Shares of Evolus Inc (EOLS)
Evolus(EOLS.US) Director Sells US$131.01K in Common Stock
$Evolus(EOLS.US)$ Director GILL DAVID N sold 10,361 shares of common stock on May 13, 14, 2024 at an average price of $12.6445 for a total value of $131.01K.Source: Announcement What is statement of c
Evolus(EOLS.US) Director Sells US$362.01K in Common Stock
$Evolus(EOLS.US)$ Director Malik Vikram sold 28,000 shares of common stock on May 13, 2024 at an average price of $12.929 for a total value of $362.01K.Source: Announcement What is statement of change
Evolus Celebrates Fifth Anniversary of Launching Its Flagship Product Jeuveau at the Women's Wear Daily Beauty CEO Summit
David Moatazedi, President and Chief Executive Officer of Evolus, is first medical aesthetics leader to be a speaker at WWD Beauty CEO Summit Evolus' flagship product, Jeuveau is the fastest growing
Form 144 | Evolus(EOLS.US) Director Proposes to Sell 362.04K in Common Stocks
SEC FILLINGS DISCLOSED/ May 14, $Evolus(EOLS.US)$ Director Malik Vikram intends to sell 28,000 shares of its common stock on May 13, with a total market value of approximately $362.04K. Source: Ann
Form 144 | Evolus(EOLS.US) Director Proposes to Sell 131.58K in Common Stocks
SEC FILLINGS DISCLOSED/ May 13, $Evolus(EOLS.US)$ Director GILL DAVID N intends to sell 10,361 shares of its common stock on May 13, with a total market value of approximately $131.58K. Source: Ann
Barclays Keeps Their Buy Rating on Evolus (EOLS)
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Evolus’ Sandra Beaver Named Orange County Business Journal’s Public Company CFO of the Year
Evolus's Strong Q1 Performance and Solid Growth Trajectory Justify Buy Rating
Evolus Outperforms Expectations With Strong Q1 Sales and Promising Growth Trajectory
Evolus First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Evolus Price Target Maintained With a $27.00/Share by HC Wainwright & Co.
Evolus Price Target Maintained With a $27.00/Share by HC Wainwright & Co.
Express News | HC Wainwright & Co. Reiterates Buy on Evolus, Maintains $27 Price Target
Evolus, Inc. (NASDAQ:EOLS) Q1 2024 Earnings Call Transcript
Q1 2024 Evolus Inc Earnings Call
Evolus Price Target Maintained With a $22.00/Share by Needham
Evolus Price Target Maintained With a $22.00/Share by Needham
Earnings Call Summary | Evolus(EOLS.US) Q1 2024 Earnings Conference
The following is a summary of the Evolus, Inc. (EOLS) Q1 2024 Earnings Call Transcript:Financial Performance:Evolus reported a Q1 2024 revenue of $59.3 million, up 42% from the prior year, indicating
Needham Reiterates Buy on Evolus, Maintains $22 Price Target
Needham analyst Serge Belanger reiterates Evolus (NASDAQ:EOLS) with a Buy and maintains $22 price target.
Evolus Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/08/2024 63.33% Needham → $22 Reiterates Buy → Buy 04/10/2024 63.33% Needham → $22 Reiterates Buy → Buy